Can early use of LAI change the course of schizophrenia? Lecture at the XXIX Conference in the series ‘Pharmacotherapy, psychotherapy and rehabilitation of affective disorders’ in Cracow 7-9.11.2024
Article Sidebar
Published:
Dec 1, 2024
Keywords:
schizophrenia, LAI, compliance, prognosis
Main Article Content
Abstract
Recurrence and duration of psychosis influence the long-term prognosis of schizophrenia. The use of prolonged-release injection drugs significantly improves compliance and regularity of treatment, and may therefore change the course of the disease. The terms of reimbursement do not limit the use of these drugs only to chronic patients, after numerous relapses and rehospitalizations.
Article Details
How to Cite
Dudek, D. (2024). Can early use of LAI change the course of schizophrenia?. Medycyna Faktow (J EBM), 17(3(64), 369-372. https://doi.org/10.24292/01.MF.0324.09
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Zipursky RB, Menezes MN, Streiner DL. Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophr Res. 2014; 152(2-3): 408-14.
2. Kozma C, Grogg A. Drug discontinuation time and the risk of hospitalization CPNP 2003; Charleston, South Carolina.
3. Herings RM, Erkenset JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf. 2003; 12: 423-4.
4. Takeuchi H, Siu C, Remington G et al. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology. 2019; 44(6): 1036-42.
5. Knapp M, Ilson A, David A. Depot antipsychotic preparations in schizophrenia: the state of the economic evidence. Int Clin Psychopharmacol. 2002; 17: 135-40.
6. Siwek M, Krupa A. Atypowe leki przeciwpsychotyczne w formie iniekcji o przedłużonym uwalnianiu. In: Nowe leki przeciwpsychotyczne. Siwek M. (ed). Medical Education, Warszawa 2020: 257-93.
7. Tiihonen J, Mittendorfer-Rutz E, Majak M et al. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia. JAMA Psychiatry. 2017; 74(7): 686-93. http://doi.org/10.1001/jamapsychiatry.2017.1322.
8. Wallman P, Clark I, Taylor D. Effect of 3-monthly paliperidone palmitate on hospitalisation in a naturalistic schizophrenia cohort - A five-year mirror image study. J Psychiatr Res. 2022; 148: 131-36. http://doi.org/10.1016/j.jpsychires.2022.01.044.
9. Boyer L, Falissard B, Nuss P et al. Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders. Mol Psychiatry. 2023; 28(9): 3709-16. http://doi.org/10.1038/s41380-023-02175-z.
10. Pappa S, Barnett J, Mason K. A 10-Year Observational Study of the Use, Acceptability and Effectiveness of Long-Acting Paliperidone Palmitate: Implications for Clinical Decision Making. CNS Drugs. 2023; 37(1): 107-16. http://doi.org/10.1007/s40263-022-00976-4.
11. Harrison G, Hopper K, Craig T et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study Br J Psychiatry. 2001; 178(6): 506-17.
12. Lieberman JA, Drake RE, Sederer LI et al. Science and recovery in schizophrenia. Psychiatr Serv. 2008; 59(5): 487-96.
13. Velligan DI, Weiden PJ, Sajatovic M et al. Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. J Clin Psychiatry. 2009; 70(suppl 4): 1-46.
14. Obwieszczenie Ministra Zdrowia z dnia 18 marca 2024 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na 1 kwietnia 2024 r.
15. Gałecki P. Udokumentowany, uporczywy brak współpracy podczas leczenia schizofrenii – rekomendacje Konsultanta Krajowego. Psychiatria Polska. 2021; 55(5): 1183-85.
2. Kozma C, Grogg A. Drug discontinuation time and the risk of hospitalization CPNP 2003; Charleston, South Carolina.
3. Herings RM, Erkenset JA. Increased suicide attempt rate among patients interrupting use of atypical antipsychotics. Pharmacoepidemiol Drug Saf. 2003; 12: 423-4.
4. Takeuchi H, Siu C, Remington G et al. Does relapse contribute to treatment resistance? Antipsychotic response in first- vs. second-episode schizophrenia. Neuropsychopharmacology. 2019; 44(6): 1036-42.
5. Knapp M, Ilson A, David A. Depot antipsychotic preparations in schizophrenia: the state of the economic evidence. Int Clin Psychopharmacol. 2002; 17: 135-40.
6. Siwek M, Krupa A. Atypowe leki przeciwpsychotyczne w formie iniekcji o przedłużonym uwalnianiu. In: Nowe leki przeciwpsychotyczne. Siwek M. (ed). Medical Education, Warszawa 2020: 257-93.
7. Tiihonen J, Mittendorfer-Rutz E, Majak M et al. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia. JAMA Psychiatry. 2017; 74(7): 686-93. http://doi.org/10.1001/jamapsychiatry.2017.1322.
8. Wallman P, Clark I, Taylor D. Effect of 3-monthly paliperidone palmitate on hospitalisation in a naturalistic schizophrenia cohort - A five-year mirror image study. J Psychiatr Res. 2022; 148: 131-36. http://doi.org/10.1016/j.jpsychires.2022.01.044.
9. Boyer L, Falissard B, Nuss P et al. Real-world effectiveness of long-acting injectable antipsychotic treatments in a nationwide cohort of 12,373 patients with schizophrenia-spectrum disorders. Mol Psychiatry. 2023; 28(9): 3709-16. http://doi.org/10.1038/s41380-023-02175-z.
10. Pappa S, Barnett J, Mason K. A 10-Year Observational Study of the Use, Acceptability and Effectiveness of Long-Acting Paliperidone Palmitate: Implications for Clinical Decision Making. CNS Drugs. 2023; 37(1): 107-16. http://doi.org/10.1007/s40263-022-00976-4.
11. Harrison G, Hopper K, Craig T et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study Br J Psychiatry. 2001; 178(6): 506-17.
12. Lieberman JA, Drake RE, Sederer LI et al. Science and recovery in schizophrenia. Psychiatr Serv. 2008; 59(5): 487-96.
13. Velligan DI, Weiden PJ, Sajatovic M et al. Expert Consensus Panel on Adherence Problems in Serious and Persistent Mental Illness. J Clin Psychiatry. 2009; 70(suppl 4): 1-46.
14. Obwieszczenie Ministra Zdrowia z dnia 18 marca 2024 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na 1 kwietnia 2024 r.
15. Gałecki P. Udokumentowany, uporczywy brak współpracy podczas leczenia schizofrenii – rekomendacje Konsultanta Krajowego. Psychiatria Polska. 2021; 55(5): 1183-85.